187 related articles for article (PubMed ID: 29438697)
1. Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.
Booth CAG; Barkas N; Neo WH; Boukarabila H; Soilleux EJ; Giotopoulos G; Farnoud N; Giustacchini A; Ashley N; Carrelha J; Jamieson L; Atkinson D; Bouriez-Jones T; Prinjha RK; Milne TA; Teachey DT; Papaemmanuil E; Huntly BJP; Jacobsen SEW; Mead AJ
Cancer Cell; 2018 Feb; 33(2):274-291.e8. PubMed ID: 29438697
[TBL] [Abstract][Full Text] [Related]
2. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
Elife; 2016 Nov; 5():. PubMed ID: 27879203
[TBL] [Abstract][Full Text] [Related]
3. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.
Danis E; Yamauchi T; Echanique K; Zhang X; Haladyna JN; Riedel SS; Zhu N; Xie H; Orkin SH; Armstrong SA; Bernt KM; Neff T
Cell Rep; 2016 Mar; 14(8):1953-65. PubMed ID: 26904942
[TBL] [Abstract][Full Text] [Related]
4. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
5. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
Mechaal A; Menif S; Abbes S; Safra I
Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
[TBL] [Abstract][Full Text] [Related]
6. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
7. Frequent coexistence of RAS mutations in RUNX1-mutated acute myeloid leukemia in Arab Asian children.
Al-Kzayer LF; Sakashita K; Al-Jadiry MF; Al-Hadad SA; Uyen le TN; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Hasan JG; Al-Abdullah HM; Inoshita T; Kamata M; Sughayer MA; Madanat FF; Koike K
Pediatr Blood Cancer; 2014 Nov; 61(11):1980-5. PubMed ID: 25066867
[TBL] [Abstract][Full Text] [Related]
8. Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.
Thanasopoulou A; Tzankov A; Schwaller J
Haematologica; 2014 Sep; 99(9):1465-71. PubMed ID: 24951466
[TBL] [Abstract][Full Text] [Related]
9. FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.
Mead AJ; Kharazi S; Atkinson D; Macaulay I; Pecquet C; Loughran S; Lutteropp M; Woll P; Chowdhury O; Luc S; Buza-Vidas N; Ferry H; Clark SA; Goardon N; Vyas P; Constantinescu SN; Sitnicka E; Nerlov C; Jacobsen SE
Cell Rep; 2013 Jun; 3(6):1766-76. PubMed ID: 23727242
[TBL] [Abstract][Full Text] [Related]
10. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
Greif PA; Konstandin NP; Metzeler KH; Herold T; Pasalic Z; Ksienzyk B; Dufour A; Schneider F; Schneider S; Kakadia PM; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
Haematologica; 2012 Dec; 97(12):1909-15. PubMed ID: 22689681
[TBL] [Abstract][Full Text] [Related]
11. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
[TBL] [Abstract][Full Text] [Related]
12. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
Stomper J; Meier R; Ma T; Pfeifer D; Ihorst G; Blagitko-Dorfs N; Greve G; Zimmer D; Platzbecker U; Hagemeijer A; Schmitt-Graeff I; Lübbert M
Clin Epigenetics; 2021 Apr; 13(1):77. PubMed ID: 33845873
[TBL] [Abstract][Full Text] [Related]
13. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
14. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status.
Silva FP; Swagemakers SM; Erpelinck-Verschueren C; Wouters BJ; Delwel R; Vrieling H; van der Spek P; Valk PJ; Giphart-Gassler M
Blood; 2009 Oct; 114(14):3001-7. PubMed ID: 19666867
[TBL] [Abstract][Full Text] [Related]
16. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
[TBL] [Abstract][Full Text] [Related]
17. A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction as Developmental Susceptibility to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1.
Böiers C; Richardson SE; Laycock E; Zriwil A; Turati VA; Brown J; Wray JP; Wang D; James C; Herrero J; Sitnicka E; Karlsson S; Smith AJH; Jacobsen SEW; Enver T
Dev Cell; 2018 Feb; 44(3):362-377.e7. PubMed ID: 29290585
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
Bluteau D; Gilles L; Hilpert M; Antony-Debré I; James C; Debili N; Camara-Clayette V; Wagner-Ballon O; Cordette-Lagarde V; Robert T; Ripoche H; Gonin P; Swierczek S; Prchal J; Vainchenker W; Favier R; Raslova H
Blood; 2011 Dec; 118(24):6310-20. PubMed ID: 21725049
[TBL] [Abstract][Full Text] [Related]
19. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.
Nick HJ; Kim HG; Chang CW; Harris KW; Reddy V; Klug CA
Blood; 2012 Feb; 119(6):1522-31. PubMed ID: 21937700
[TBL] [Abstract][Full Text] [Related]
20. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
Cammenga J; Niebuhr B; Horn S; Bergholz U; Putz G; Buchholz F; Löhler J; Stocking C
Cancer Res; 2007 Jan; 67(2):537-45. PubMed ID: 17234761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]